Thomas Walther
Research Laboratories of Schering AG
Experimental Oncology
13342 Berlin
Germany
Name/email consistency: high
- Differential regulation of in vivo angiogenesis by angiotensin II receptors. Walther, T., Menrad, A., Orzechowski, H.D., Siemeister, G., Paul, M., Schirner, M. FASEB J. (2003)
- Fibrosis rather than blood pressure determines cardiac BNP expression in mice. Walther, T., Klostermann, K., Heringer-Walther, S., Schultheiss, H.P., Tschöpe, C., Stepan, H. Regul. Pept. (2003)
- Ischemic injury in experimental stroke depends on angiotensin II. Walther, T., Olah, L., Harms, C., Maul, B., Bader, M., Hörtnagl, H., Schultheiss, H.P., Mies, G. FASEB J. (2002)
- Fetal, neonatal cord, and maternal plasma concentrations of angiotensin-converting enzyme (ACE). Walther, T., Faber, R., Maul, B., Schultheiss, H.P., Siems, W.E., Stepan, H. Prenat. Diagn. (2002)
- Natriuretic peptide system in fetal heart and circulation. Walther, T., Schultheiss, H.P., Tschöpe, C., Stepan, H. J. Hypertens. (2002)
- AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats. Walther, T., Siems, W.E., Hauke, D., Spillmann, F., Dendorfer, A., Krause, W., Schultheiss, H.P., Tschöpe, C. FASEB J. (2002)









